SI-BONE, Inc. 8K

SI-BONE, Inc. announced strong first quarter 2026 results and raised its full-year 2026 revenue and gross margin guidance while maintaining expectations for positive adjusted EBITDA.

SI-BONE, Inc. reported its financial results for the quarter ended March 31, 2026, highlighting 11.2% year-over-year worldwide revenue growth to $52.6 million, stable gross margin of 79.8%, a reduced net loss of $4.3 million, and a more than fourfold improvement in adjusted EBITDA to $2.5 million, supported by increased physician adoption, expanded international presence for its iFuse TORQ product line, and favorable proposed CMS reimbursement for complex spinal fusion procedures; based on this performance, the company raised its full-year 2026 revenue guidance to a range of $230–$233 million and increased expected gross margin to approximately 79% while reaffirming expectations for positive adjusted EBITDA.

Filing Facts

CIK

1459839

Ticker

-

Form

8K

Source Type

sec

Accession

0001459839-26-000054

Alert Tier

7